0 paragraphs of its Risk Factors mention AI, against 0 the year before.
Compare companies, side by side
The same facts from the filings for each company in a group, where each stands among the others, and what each wrote about a topic in its latest 10-K.
- Sales growth
- +7.1%
- Gross margin
- 65%
- Operating margin
- 14%
- Net margin
- 9.6%
The 3 largest with TECH, ranked among the group
Each corner is the share of Health care companies the company is above on that ratio. The dashed line is the middle of the group. A rank, not a score.
10 paragraphs of its Risk Factors mention AI, against 7 the year before.
8 paragraphs of its Risk Factors mention AI, against 5 the year before.
Health care: the same facts for each company
| Company | Revenue, 12 months | Sales growth | Gross / operating margin | Net margin | Debt / equity | Accounting items | Insider buys | Investors | Open |
|---|---|---|---|---|---|---|---|---|---|
| TECHYou came from Bio-Techne | $1.2B
|
-0.4% |
GM 66%OM 20%
|
14% | 0.18 | 0 of 6to read | 0 | 0 | 10-K |
| UNH UnitedHealth Group | $449.7B
|
+12% |
GM 88%OM 5.3%
|
3.5% | 0.71 | 1 of 5to read | 0 | 0 | 10-K |
| CVS CVS Health | $420.6B
|
+7.8% |
GM 44%OM 3.6%
|
2.6% | 0.75 | 0 of 6to read | 1 | 0 | 10-K |
| MCK McKesson | $418.8B
|
+12% |
GM 3.7%OM 1.6%
|
1.1% | - | 0 of 6to read | 0 | 0 | 10-K |
| COR Cencora | $332.8B
|
+9.3% |
GM 4.0%OM 0.9%
|
0.8% | 3.93 | 0 of 6to read | 0 | 0 | 10-K |
| CI Cigna | $286.3B
|
+11% |
GM 21%OM 3.4%
|
2.1% | 0.68 | 0 of 4to read | 0 | 0 | 10-K |
| CAH Cardinal Health | $257.8B
|
+14% |
GM 3.9%OM 1.0%
|
0.7% | - | 0 of 6to read | 0 | 0 | 10-K |
| CNC Centene Corporation | $203.9B
|
+19% |
GM 7.9%OM 0.5%
|
0.7% | 0.70 | 1 of 3to read | 0 | 0 | 10-K |
| ELV Elevance Health | $201.8B
|
+12% |
GM 89%OM 2.7%
|
2.5% | 0.69 | 0 of 3to read | 0 | 0 | 10-K |
| HUM Humana | $154.2B
|
+10% |
GM -OM 1.5%
|
0.8% | 0.66 | 1 of 4to read | 0 | 0 | 10-K |
| JNJ Johnson & Johnson | $99.3B
|
+6.0% |
GM 68%OM -
|
16% | 0.55 | 1 of 6to read | 0 | 0 | 10-K |
| LLY Eli Lilly | $86.5B
|
+45% |
GM 84%OM -
|
32% | 1.23 | 3 of 6to read | 0 | 0 | 10-K |
| HCA HCA Healthcare | $78.7B
|
+7.1% |
GM -OM -
|
8.6% | - | 0 of 6to read | 0 | 0 | 10-K |
| MRK Merck & Co. | $67.4B
|
+1.3% |
GM 72%OM -
|
3.6% | 1.20 | 2 of 6to read | 0 | 0 | 10-K |
| ABBV AbbVie | $66.0B
|
+8.6% |
GM 74%OM 32%
|
16% | - | 1 of 6to read | 0 | 0 | 10-K |
| PFE Pfizer | $63.6B
|
-1.6% |
GM 73%OM -
|
6.3% | 0.70 | 0 of 6to read | 0 | 0 | 10-K |
| BMY Bristol Myers Squibb | $50.0B
|
-0.2% |
GM 69%OM -
|
18% | 1.86 | 0 of 5to read | 0 | 0 | 10-K |
| ABT Abbott Laboratories | $48.2B
|
+5.7% |
GM 57%OM 14%
|
9.7% | 0.61 | 0 of 6to read | 0 | 0 | 10-K |
| TMO Thermo Fisher Scientific | $47.4B
|
+3.9% |
GM -OM 18%
|
15% | 0.79 | 0 of 6to read | 0 | 0 | 10-K |
| AMGN Amgen | $38.9B
|
+10.0% |
GM 71%OM 32%
|
24% | 3.76 | 1 of 6to read | 0 | 0 | 10-K |
| MDT Medtronic | $37.5B
|
+8.4% |
GM 65%OM 18%
|
14% | 0.56 | 0 of 6to read | 0 | 0 | 10-K |
| GILD Gilead Sciences | $31.0B
|
+2.4% |
GM 80%OM -7.6%
|
-12% | 2.01 | 0 of 6to read | 0 | 0 | 10-K |
| SYK Stryker Corporation | $26.3B
|
+11% |
GM 65%OM 21%
|
14% | 0.61 | 1 of 6to read | 0 | 0 | 10-K |
| DHR Danaher Corporation | $25.6B
|
+2.9% |
GM 59%OM 20%
|
17% | 0.53 | 0 of 6to read | 0 | 0 | 10-K |
| BDX Becton Dickinson | $22.5B
|
+8.2% |
GM 47%OM 11%
|
4.2% | 0.69 | 0 of 6to read | 0 | 0 | 10-K |
| GEHC GE HealthCare | $21.6B
|
+4.8% |
GM 40%OM 13%
|
10.0% | 0.86 | 2 of 5to read | 0 | 0 | 10-K |
| BSX Boston Scientific | $21.1B
|
+20% |
GM 69%OM 19%
|
17% | 0.47 | 1 of 6to read | 1 | 0 | 10-K |
| UHS Universal Health Services | $18.4B
|
+9.7% |
GM -OM 11%
|
8.0% | 0.75 | 0 of 5to read | 0 | 0 | 10-K |
| IQV IQVIA | $17.3B
|
+5.9% |
GM -OM 13%
|
8.1% | 2.41 | 0 of 5to read | 0 | 0 | 10-K |
| REGN Regeneron Pharmaceuticals | $16.9B
|
+1.0% |
GM -OM 29%
|
29% | 0.06 | 0 of 6to read | 0 | 0 | 10-K |
| VTRS Viatris | $14.7B
|
-3.0% |
GM 35%OM 0.0%
|
-4.1% | 0.97 | 0 of 5to read | 0 | 0 | 10-K |
| LH Labcorp | $14.6B
|
+7.2% |
GM 29%OM 10%
|
6.9% | 0.66 | 0 of 6to read | 0 | 0 | 10-K |
| DVA DaVita | $14.2B
|
+6.5% |
GM -OM 15%
|
6.5% | - | 1 of 6to read | 0 | 0 | 10-K |
| HSIC Henry Schein | $13.7B
|
+4.0% |
GM 32%OM 5.2%
|
3.1% | 1.12 | 1 of 6to read | 0 | 0 | 10-K |
| VRTX Vertex Pharmaceuticals | $13.0B
|
+8.9% |
GM 86%OM 33%
|
31% | 0.22 | 4 of 6to read | 0 | 0 | 10-K |
| DGX Quest Diagnostics | $11.8B
|
+12% |
GM 33%OM 15%
|
9.5% | 0.73 | 0 of 6to read | 0 | 0 | 10-K |
| BAX Baxter International | $11.6B
|
+5.7% |
GM 30%OM -1.9%
|
-6.2% | 1.45 | 1 of 6to read | 0 | 0 | 10-K |
| ISRG Intuitive Surgical | $11.6B
|
+21% |
GM 67%OM 28%
|
26% | - | 0 of 6to read | 0 | 0 | 10-K |
| BIIB Biogen | $10.3B
|
+2.2% |
GM 74%OM -
|
3.4% | 0.39 | 0 of 6to read | 0 | 0 | 10-K |
| ZTS Zoetis | $9.5B
|
+2.3% |
GM 72%OM -
|
26% | 2.74 | 1 of 6to read | 0 | 0 | 10-K |
| ZBH Zimmer Biomet | $8.6B
|
+7.2% |
GM 70%OM 14%
|
9.0% | 0.59 | 1 of 6to read | 0 | 0 | 10-K |
| SOLV Solventum | $8.2B
|
+0.9% |
GM 55%OM 5.5%
|
1.9% | 0.95 | 2 of 6to read | 0 | 0 | 10-K |
| A Agilent Technologies | $7.4B
|
+6.7% |
GM 54%OM 22%
|
20% | 0.54 | 1 of 6to read | 0 | 0 | 10-K |
| EW Edwards Lifesciences | $6.7B
|
+12% |
GM 78%OM 22%
|
15% | 0.06 | 0 of 6to read | 0 | 0 | 10-K |
| STE Steris | $6.2B
|
+8.7% |
GM 45%OM 19%
|
13% | 0.26 | 0 of 6to read | 0 | 0 | 10-K |
| INCY Incyte | $6.0B
|
+21% |
GM 93%OM 10%
|
6.7% | - | 1 of 6to read | 0 | 0 | 10-K |
| RMD ResMed | $5.7B
|
+9.9% |
GM 61%OM 33%
|
28% | 0.07 | 1 of 6to read | 0 | 0 | 10-K |
| WAT Waters Corporation | $5.6B
|
+7.0% |
GM 59%OM 4.7%
|
1.8% | 0.34 | 1 of 6to read | 0 | 0 | 10-K |
| DXCM Dexcom | $5.1B
|
+16% |
GM 63%OM 24%
|
19% | - | 2 of 6to read | 0 | 0 | 10-K |
| IDXX Idexx Laboratories | $4.7B
|
+10% |
GM 63%OM 32%
|
25% | 0.20 | 0 of 6to read | 0 | 0 | 10-K |
| ILMN Illumina, Inc. | $4.5B
|
-0.7% |
GM 68%OM 21%
|
20% | 0.57 | 2 of 6to read | 0 | 0 | 10-K |
| COO Cooper Companies | $4.2B
|
+5.1% |
GM 66%OM 13%
|
13% | 0.31 | 1 of 6to read | 5 | 0 | 10-K |
| MTD Mettler Toledo | $4.2B
|
+4.0% |
GM 60%OM -
|
22% | - | 0 of 6to read | 0 | 0 | 10-K |
| ALGN Align Technology | $4.2B
|
+0.9% |
GM 69%OM 15%
|
12% | - | 0 of 6to read | 0 | 0 | 10-K |
| CRL Charles River Laboratories | $4.0B
|
-0.9% |
GM -OM 4.0%
|
1.0% | 0.76 | 0 of 6to read | 1 | 0 | 10-K |
| VEEV Veeva Systems | $3.5B
|
+16% |
GM 75%OM 30%
|
29% | - | 0 of 5to read | 0 | 0 | 10-K |
| WST West Pharmaceutical Services | $3.4B
|
+6.3% |
GM 38%OM 23%
|
19% | 0.07 | 1 of 6to read | 0 | 0 | 10-K |
| PODD Insulet Corporation | $3.2B
|
+31% |
GM 72%OM 18%
|
13% | 0.61 | 1 of 4to read | 1 | 0 | 10-K |
| RVTY Revvity | $2.9B
|
+3.7% |
GM -OM 13%
|
8.6% | 0.36 | 1 of 6to read | 0 | 0 | 10-K |
| MRNA Moderna | $2.5B
|
-40% |
GM 28%OM -116%
|
-110% | 0.09 | 1 of 6to read | 0 | 0 | 10-K |
Growth against cash margin
The 14 largest by revenue. A bigger bubble is more revenue; the dashed lines are the median of these companies.
How to read this page
- A radar shows where a company ranks among its group on six ratios. A corner at the edge means it is above every other company on that ratio.
- A table row lists the facts as the filings give them: revenue, growth, margins, debt to equity, the accounting checks, insider buying and followed investors holding.
- A bubble to the right grew faster, and one higher up kept more of its sales as free cash flow.
- A bar is paragraphs that mention the topic this year, and the mark on it is last year.
Risk Factors and XBRL figures from each company's latest 10-K, read nightly from SEC EDGAR. Nothing here is a rating.
AI: paragraphs that mention it
All 79 companies
Risk Factors paragraphs in each company's latest 10-K, most mentions first. The bar is this year and the mark is last year. 83 companies have no 10-K downloaded yet.
What the companies wrote
HSIC HENRY SCHEIN INC
30 paragraphsWe have increased and expect to continue to increase our use of AI technologies in various contexts to improve
Item 1A, Risk Factors, 10-K Feb 24, 2026
applying their data and consumer protection laws to AI, particularly generative AI, and are considering and
10-K, 10-K Feb 24, 2026
GEHC GE HealthCare Technologies Inc.
27 paragraphsA growing part of our business involves cloud, edge computing, AI (including generative AI), and software solutions, and we are devoting significant resources to developing and deploying such strategies. Our success with these solutions will depend on the level of …
Item 1A, Risk Factors, 10-K Feb 4, 2026
Additionally, we are making significant investments in AI initiatives and are building AI into many of our digital offerings. We are planning to use AI, including generative AI, throughout our portfolios to build differentiated products and solutions and deploy those …
Item 1A, Risk Factors, 10-K Feb 4, 2026
IQV IQVIA HOLDINGS INC.
25 paragraphsIn addition, the emergence of the use of Real World Evidence and the advancements in new approaches such as machine learning and artificial intelligence (AI), including generative, agentic and foundation models that are increasingly accessible through third‑party or open …
Item 1A, Risk Factors, 10-K Feb 17, 2026
… We are committed to using artificial intelligence ("AI") responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by …
Item 7, MD&A, 10-K Feb 17, 2026
MRNA Moderna, Inc.
23 paragraphsOur use of generative AI ("GenAI") and other AI technologies presents certain risks and challenges given the emerging nature of AI technologies.
Item 1A, Risk Factors, 10-K Feb 20, 2026
… At the same time, the Trump Administration has endorsed a federal moratorium on the enforcement of state AI laws, including through an executive order on “Ensuring a National Policy Framework for Artificial Intelligence.” So far, these efforts have not been …
Item 1A, Risk Factors, 10-K Feb 20, 2026
IDXX IDEXX LABORATORIES INC /DE
21 paragraphs… In August 2024, the European Union Artificial Intelligence Act, which establishes requirements for the provision and use of products that leverage AI, machine learning, and similar technologies was enacted and will become fully effective in August 2026, with some provisions …
Item 1A, Risk Factors, 10-K Feb 20, 2026
• Continuing to responsibly incorporate AI, machine learning, and automation into our products and services and associated business processes, such as customer support and software development;
Item 1A, Risk Factors, 10-K Feb 20, 2026
ALGN ALIGN TECHNOLOGY INC
19 paragraphsAI and machine learning technologies in our products, services and IT systems may result in legal and regulatory risks, reputational harm or have other adverse consequences to our business.
Item 1A, Risk Factors, 10-K Feb 27, 2026
We have and are continuing to incorporate AI and machine learning technologies into certain of our products, services and IT systems, while continuing to explore the opportunities that AI could bring to our company. However, there can be no assurance …
Item 1A, Risk Factors, 10-K Feb 27, 2026
Show all 79 companies' quotes
RMD RESMED INC
19 paragraphs… We increasingly incorporate artificial intelligence, or AI, including machine learning, into certain products, software solutions and business processes to enhance patient engagement, support clinical workflows and improve operational efficiencies. AI-enabled features may not perform as intended and could produce …
Item 1A, Risk Factors, 10-K Aug 13, 2026
… Such cyberattacks increasingly exploit AI and machine-learning techniques - ranging from generative-AI phishing and deep-fake impersonations to automated vulnerability discovery, adaptive malware and large-scale credential-stuffing campaigns - each of which can evolve rapidly to evade traditional security …
Item 1A, Risk Factors, 10-K Aug 13, 2026
ISRG INTUITIVE SURGICAL INC
18 paragraphsOur current operations, products, and services use AI technologies, including proprietary machine learning and AI algorithms and models. Examples of our current uses of AI and machine learning include (i) using algorithms to process video and machine data to identify …
Item 1A, Risk Factors, 10-K Feb 3, 2026
The regulatory landscape surrounding AI is also evolving, and the use of machine learning technologies may expose us to an increased risk of regulatory enforcement and litigation. As the FDA and other regulatory authorities continue to develop and incorporate such …
Item 1A, Risk Factors, 10-K Feb 3, 2026
PFE PFIZER INC
18 paragraphsAI, including machine learning and generative AI, is increasingly being used in the biopharmaceutical and global healthcare industries. We have begun deploying AI in various parts of our internal and external operations, including in R&D, and continue to explore …
Item 1A, Risk Factors, 10-K Feb 26, 2026
may also lead to the unauthorized release of confidential or proprietary information which may impact our ability to realize the benefits of our data, including intellectual property. Further, reliance on third-party AI tools or services that incorporate AI may expose our organization to compliance gaps that are outside of our control. In addition, we could face risks related to our reliance on a small number of AI models or service providers.
Item 1A, Risk Factors, 10-K Feb 26, 2026
BDX BECTON DICKINSON & CO
17 paragraphsWe have integrated (and expect to continue to integrate) AI into our products and business operations generally. We also expect to continue to develop future uses of AI and expand our existing AI capabilities to include agentic solutions, as well as pursue new AI technology partnerships with third parties. The development, deployment and use of AI (particularly generative AI) is in the early stages and presents various
Item 1A, Risk Factors, 10-K Nov 25, 2025
• Accelerating innovation in smart devices, robotics, analytics, and artificial intelligence in order to enable new care settings, improve outcomes, streamline care workflows, and reduce costs within healthcare settings;
Item 7, MD&A, 10-K Nov 25, 2025
CI Cigna Group
17 paragraphsOur use of artificial intelligence and machine learning present regulatory and legal challenges that could negatively affect our business and our reputation.
Item 1A, Risk Factors, 10-K Feb 26, 2026
Our use of AI and ML technologies, as well as more recent technological advances in AI/ML, pose risks to us and subject us to new and existing laws and regulations. The use of generative AI, a relatively new and …
Item 1A, Risk Factors, 10-K Feb 26, 2026
DGX QUEST DIAGNOSTICS INC
17 paragraphsWe have been and expect to continue to use AI technology in our testing services, and we anticipate it will become increasingly important to us over time. This technology, including generative AI, which is in its early stages of broader …
Item 1A, Risk Factors, 10-K Feb 26, 2026
(p) Challenges, including the associated competitive pressures, with properly managing the development, implementation, oversight and use of AI.
Item 1A, Risk Factors, 10-K Feb 26, 2026
MDT Medtronic plc
15 paragraphs… This includes continued integration and adoption of Touch Surgery Enterprise with the first artificial intelligence (AI) powered surgical videos and analytics platform to make it easier to analyze performance, train, and discover new techniques within the robotics platform. The Hugo …
Item 7, MD&A, 10-K Jun 18, 2026
… For example, data science, machine learning and AI are all impacting our products and operations and the competitive landscape in which we operate, and the application of these technologies is rapidly evolving at the same time as new laws and …
Item 1A, Risk Factors, 10-K Jun 18, 2026
VEEV VEEVA SYSTEMS INC
15 paragraphsAs we increase the number of products we offer, increase the number of countries in which we operate, and incorporate new technologies and capabilities into our products (including the use of AI and machine learning technologies), the complexity of adjusting our solutions to comply with legal and regulatory changes will increase. If we are unable to effectively manage this increased complexity or if we are not able to provide solutions that can be
Item 1A, Risk Factors, 10-K Mar 20, 2026
… Furthermore, new and evolving regulations relating to the use of data in AI and machine learning technologies, such as the EU AI Act, are creating an increasingly complex and fragmented regulatory framework.
Item 1A, Risk Factors, 10-K Mar 20, 2026
BAX BAXTER INTERNATIONAL INC
14 paragraphsWe use both internally developed and third party-provided AI and machine learning (ML) technologies to support our functions and operations (including Generative AI tools) and anticipate integrating such technology in select products and services in the future (consistent with …
Item 1A, Risk Factors, 10-K Feb 12, 2026
• We are exposed to risks associated with incorporating AI, machine learning and other emerging technologies into our products, services and operations.
Item 1A, Risk Factors, 10-K Feb 12, 2026
HCA HCA Healthcare, Inc.
14 paragraphs… Some states have adopted or are considering additional measures regarding the use of AI within the health care industry. For example, California’s AB 3030 requires that certain disclaimers and instructions be provided to patients if generative AI is used …
Item 1A, Risk Factors, 10-K Feb 10, 2026
… In particular, AI is driving innovation and, in some cases, augmenting risks related to health care technology. For example, our physicians are adopting the use of generative AI to assist with the taking of patient medical notes, among other tasks …
Item 1A, Risk Factors, 10-K Feb 10, 2026
MCK MCKESSON CORP
13 paragraphs… Additionally, some of our historical competitors and a growing number of new competitive entrants have more experience than we do in enabling technologies such as data analytics, machine learning, or AI. As described in “Government Regulation” in Item 1 of …
Item 1A, Risk Factors, 10-K May 8, 2026
We increasingly rely on technologies powered by or incorporating AI in our internal operations and business processes. The use of AI technologies introduces risks and uncertainties. AI can generate outputs that are false, misleading, incomplete, biased, or inconsistent. AI performance …
Item 1A, Risk Factors, 10-K May 8, 2026
CNC CENTENE CORP
12 paragraphs• innovations in technology in the health service industry, including the use of artificial intelligence and machine learning.
Item 1A, Risk Factors, 10-K Feb 17, 2026
… Changes to laws and regulations regarding how we may use artificial intelligence could make it harder for us to conduct our business using artificial intelligence; require us to retrain our artificial intelligence; or prevent or limit our use of artificial …
Item 1A, Risk Factors, 10-K Feb 17, 2026
LH LABCORP HOLDINGS INC.
11 paragraphsThe use of AI and machine learning tools in the Company’s operations and the services of third-parties may introduce risks that could adversely affect the Company’s business, financial condition, and reputation.
Item 1A, Risk Factors, 10-K Feb 24, 2026
The Company and certain of its third-party vendors use AI and machine learning tools to enhance productivity and innovation, but these technologies also introduce risks. Improper use may lead to data leaks of sensitive, proprietary, or confidential information, flawed …
Item 1A, Risk Factors, 10-K Feb 24, 2026
TMO THERMO FISHER SCIENTIFIC INC.
11 paragraphs… For example, we are incorporating AI and machine learning technologies into our products, services and internal processes. Failure to keep pace with rapid developments in AI technologies could adversely affect our competitive position and results of operations. If we fail …
Item 1A, Risk Factors, 10-K Feb 26, 2026
… health issues, geopolitical developments, war, terrorist actions, cybersecurity incidents including but not limited to ransomware attacks, misuse of AI and machine learning technologies, governmental actions and legislative or regulatory changes. Any of these factors could result in production interruptions, delays …
Item 1A, Risk Factors, 10-K Feb 26, 2026
ZBH ZIMMER BIOMET HOLDINGS, INC.
11 paragraphsFurther, our use of artificial intelligence and machine learning in our infrastructure and products exposes us to a variety of threats, risks and uncertainties, including with respect to changing laws and regulations regarding the use of such technologies; the risks …
Item 1A, Risk Factors, 10-K Feb 20, 2026
… Emerging opportunities, including those presented by the use of machine learning and artificial intelligence in our current and future products, devices and services are expected to present new, complex and potentially inconsistent legal and regulatory requirements across the various jurisdictions …
Item 1A, Risk Factors, 10-K Feb 20, 2026
AMGN AMGEN INC
10 paragraphs… Further, several governments and regulatory authorities have proposed or passed laws and regulations governing the use of AI. For example, the European Parliament has adopted the Artificial Intelligence Act establishing EU-wide rules on data quality, transparency, human oversight and …
Item 1A, Risk Factors, 10-K Feb 13, 2026
To achieve our business objectives, we rely on sophisticated information technology systems, including hardware, software, technology infrastructure, online sites and networks for both internal and external operations, mobile applications, cloud services, artificial intelligence (AI)-enabled tools and systems, and network …
Item 1A, Risk Factors, 10-K Feb 13, 2026
COR Cencora, Inc.
10 paragraphsRegulatory frameworks governing AI are rapidly evolving and may impose significant obligations on our development, deployment, and use of AI. In particular, the EU’s Artificial Intelligence Act imposes requirements on AI system providers, importers, distributors, and users, as well …
Item 1A, Risk Factors, 10-K Nov 25, 2025
… For example, as AI continues to evolve, cyber attackers could also use AI to develop malicious code and sophisticated phishing attempts, and our use of AI could increase cybersecurity and data protection risks. As a result, cyber security and the …
Item 1A, Risk Factors, 10-K Nov 25, 2025
DHR DANAHER CORP /DE/
10 paragraphsWe are in the early stages of incorporating AI, including machine learning technologies, into our business activities and our product and service offerings. As with many innovations, AI presents risks and challenges that could adversely impact our business. The development …
Item 1A, Risk Factors, 10-K Feb 24, 2026
Compliance with new or changing laws, regulations or industry standards relating to AI may impose significant costs and may limit our ability to develop, deploy or use AI technologies. Failure to appropriately respond to this evolving landscape may result in legal liability, regulatory action, or brand and reputational harm.
Item 1A, Risk Factors, 10-K Feb 24, 2026
UNH UNITEDHEALTH GROUP INC
10 paragraphs… We anticipate that fast-evolving AI technologies, including generative AI, will play an increasingly important role in our information systems and customer-facing technology products. Our ability to protect and enhance existing systems and develop new systems to keep pace …
Item 1A, Risk Factors, 10-K Mar 2, 2026
We increasingly rely on new and evolving technologies, including those powered by or incorporating AI, as part of our internal operations and in the delivery of our products and services. AI technologies are subject to evolving and uncertain U.S. federal, state, and international laws and regulations. Emerging requirements may impose new compliance obligations, increase operating costs, or limit certain uses of AI.
Item 1A, Risk Factors, 10-K Mar 2, 2026
VTRS Viatris Inc
10 paragraphsML and AI-based solutions, including generative AI, are increasingly being used in the pharmaceutical industry, including by us, and we expect to use other systems and tools that incorporate ML or AI-based technologies in the future. The rapidly …
Item 1A, Risk Factors, 10-K Feb 26, 2026
The deployment of AI in regulated environments presents additional complexity. Requirements related to validation, documentation, explainability, data lineage, and change control may lengthen implementation timelines, increase costs, or trigger regulatory scrutiny, audit findings, or enforcement actions. As regulatory expectations continue to mature globally, organizations must ensure that AI adoption aligns with existing compliance obligations and risk management frameworks.
Item 1A, Risk Factors, 10-K Feb 26, 2026
ZTS Zoetis Inc.
10 paragraphsWe use machine learning and AI in various business operations, and inability to successfully monitor and manage its use could result in operational, competitive or reputational harm, regulatory enforcement, and legal liability.
Item 1A, Risk Factors, 10-K Feb 12, 2026
We incorporate (and expect to continue incorporating) AI capabilities in the development of new technologies and products and continue to expand the use of AI in our business and operations. Generative AI technologies are new and rapidly evolving technologies that …
Item 1A, Risk Factors, 10-K Feb 12, 2026
DXCM DEXCOM INC
9 paragraphsAs part of our commitment to technological advancement, we have incorporated and will continue to explore and implement AI-enabled functions into our products and services. We continue to explore how best to leverage and harness the efficiency and innovation …
Item 1A, Risk Factors, 10-K Feb 12, 2026
Moreover, we are subject to various operational, compliance, and reputational risks associated with our adoption and utilization of AI technologies, including inaccurate or unpredictable outputs, such as errors or hallucinations, that may impair decision‑making, disrupt operations, or expose sensitive …
Item 1A, Risk Factors, 10-K Feb 12, 2026
ELV Elevance Health, Inc.
9 paragraphs… Our information systems require an ongoing investment, commitment of significant resources to maintain, integrate, upgrade, enhance and expand existing systems, and development of new systems, including systems powered by or incorporating AI and machine learning (including generative AI), to keep …
Item 1A, Risk Factors, 10-K Feb 6, 2026
As part of our operations, we are making investments in certain AI tools and solutions to enhance our operations and positively impact the experience of our members, and we continue to explore further innovation using AI. The rapid advancement of …
Item 1A, Risk Factors, 10-K Feb 6, 2026
RVTY REVVITY, INC.
9 paragraphsWe are advancing AI across our product and service offerings, and we are in the initial phases of expanding AI into the core functions of our business. The development and deployment of AI presents both risks and opportunities, and the …
Item 1A, Risk Factors, 10-K Feb 24, 2026
Uncertainties related to the development, deployment and use of AI to advance our product offerings and improve internal operations may result in harm to our business and reputation.
Item 1A, Risk Factors, 10-K Feb 24, 2026
SOLV Solventum Corp
9 paragraphsThe deployment and use of artificial intelligence ("AI"), machine learning, or other emerging technologies in Solventum’s products and services, including as part of its research and development efforts, or its failure to adapt its products or services to industry trends and developments related to such technologies in a timely manner, or at all, could adversely affect Solventum’s business, financial condition, results of operations and cash flows.
Item 1A, Risk Factors, 10-K Feb 27, 2026
… For example, Solventum has incorporated AI into certain products in the Health Information Systems business segment and certain of its digital offerings and expects to continue to build AI into additional products. Any disruption or failure in the AI, machine …
Item 1A, Risk Factors, 10-K Feb 27, 2026
WAT WATERS CORP /DE/
9 paragraphsThe Company continues to integrate artificial intelligence (“AI”), including generative AI, into its business operations and products and research further uses and opportunities for AI development. As AI is a rapidly developing technology that is still in the early stages …
Item 1A, Risk Factors, 10-K Feb 23, 2026
Laws and regulations arising from the use and development of AI technology present additional uncertainties and risks to the Company. In particular, the use and development of AI implicates risks related to intellectual property, data protection and privacy laws and …
Item 1A, Risk Factors, 10-K Feb 23, 2026
CVS CVS HEALTH Corp
8 paragraphsOur business success and operating results depend in part on effective information technology systems and on continuing to develop and implement improvements in technology, including technology related to artificial intelligence (“AI”). The failure or disruption of our information technology systems or the failure of our information technology infrastructure to support our businesses could adversely affect our reputation, businesses, operating results and cash flows.
Item 1A, Risk Factors, 10-K Feb 10, 2026
The use of AI and related technology may also increase exposure to reputational, cybersecurity, data privacy, legal, regulatory and operational risks as AI technology rapidly evolves along with public opinion concerning the use of AI and the associated legal and …
Item 1A, Risk Factors, 10-K Feb 10, 2026
DVA DAVITA INC.
8 paragraphs… service providers upon which we rely or failing to successfully adopt or adapt to new technologies, including artificial intelligence and machine learning, or new treatments and therapies could materially adversely affect our business, results of operations, financial condition and cash …
Item 1A, Risk Factors, 10-K Feb 11, 2026
… For example, healthcare companies, including our Company and certain of our third-party service providers, strategic partners, consultants and contractors, are increasingly incorporating into information technology capabilities machine learning or automation for real-time prevention utilizing artificial intelligence for anomaly …
Item 1A, Risk Factors, 10-K Feb 11, 2026
ILMN ILLUMINA, INC.
8 paragraphs… Additionally, the use of artificial intelligence (AI) based software is increasingly common. Use of AI based software may lead to the inadvertent release of confidential proprietary information which may impact our ability to realize the benefit of our intellectual property.
Item 1A, Risk Factors, 10-K Feb 12, 2026
We have incorporated, and expect to continue to incorporate, artificial intelligence (AI) into our business activities and our product and service offerings. As with many innovations, AI presents risks and challenges that could adversely impact our business. The development, adoption …
Item 1A, Risk Factors, 10-K Feb 12, 2026
LLY ELI LILLY & Co
8 paragraphsOur use of artificial intelligence (AI) or other emerging technologies could adversely impact us.
Item 1A, Risk Factors, 10-K Feb 12, 2026
… Several governmental authorities have already proposed or enacted laws and other guidance governing AI, such as the EU Artificial Intelligence Act. These and other developing obligations create uncertainty and may prevent or make it harder for us to conduct or …
Item 1A, Risk Factors, 10-K Feb 12, 2026
BMY BRISTOL MYERS SQUIBB CO
7 paragraphsIn addition, we face certain risks as we seek to leverage artificial intelligence programs and machine learning (“AI”) to optimize productivity and efficiency in various aspects of the organization. For example, flawed algorithms and/or biased, incomplete or inaccurate data …
Item 1A, Risk Factors, 10-K Feb 11, 2026
… standards; (vii) cybersecurity and data protection, storage and privacy, particularly in the EU and the U.S.; (viii) artificial intelligence, machine learning, automated decision-making, data governance, and related technologies; (ix) requirements for reporting payments and other value transfers to …
Item 1A, Risk Factors, 10-K Feb 11, 2026
CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
7 paragraphsAdditionally, the rapid ongoing evolution and increased adoption of emerging technologies such as artificial intelligence and machine learning may make it more difficult to anticipate and implement protective measures to recognize, detect, and prevent the occurrence of any of the cyber events described above.
Item 1A, Risk Factors, 10-K Feb 18, 2026
We, along with many businesses in the biopharmaceutical industry, are adopting and exploring the use of artificial intelligence (AI) in our business, and as an emerging and rapidly evolving technology, our use of AI introduces potential opportunities but also presents …
Item 1A, Risk Factors, 10-K Feb 18, 2026
PODD INSULET CORP
6 paragraphsWe develop, license from other developers, and deploy AI tools, including generative AI tools for use in our operations. Our teams collaborate on the development of responsible AI policies and practices and deployment of AI tools in accordance with those …
Item 1A, Risk Factors, 10-K Feb 18, 2026
We are subject to complex and evolving laws and regulations regarding privacy, data protection, and artificial intelligence (“AI”), many of which are subject to change and uncertain interpretation, which could result in legal claims, changes to our business practices, monetary penalties, increased cost of operations, or declines in user growth or engagement.
Item 1A, Risk Factors, 10-K Feb 18, 2026
VRTX VERTEX PHARMACEUTICALS INC / MA
6 paragraphsdevelopments in the threat landscape include the use of adversarial artificial intelligence techniques and machine learning, as
Item 1A, Risk Factors, 10-K Feb 13, 2026
• our ability to effectively implement artificial intelligence systems and tools;
Item 1A, Risk Factors, 10-K Feb 13, 2026
A AGILENT TECHNOLOGIES, INC.
5 paragraphsWe are integrating artificial intelligence and machine learning technologies ("AI") into our business operations, products and services, while continuing to explore the opportunities that AI could bring to the company. The use of AI, particularly generative AI, presents opportunities as …
Item 1A, Risk Factors, 10-K Dec 22, 2025
Use of AI to improve internal business operations, or in the development or provision of products or services, poses risks and challenges. AI can pose risks from an intellectual property, confidential data leakage, data protection and privacy perspective, as well …
Item 1A, Risk Factors, 10-K Dec 22, 2025
EW Edwards Lifesciences Corp
5 paragraphs• Use of, or failure to effectively and timely utilize, emerging technologies, including artificial intelligence (“AI”)
Item 1A, Risk Factors, 10-K Feb 25, 2026
We use AI and other emerging technologies in various facets of our operations and our business. The legal and regulatory landscape surrounding AI technologies is rapidly evolving and uncertain. The rapid advancement of these technologies entails risks, including potential deficiencies …
Item 1A, Risk Factors, 10-K Feb 25, 2026
GILD GILEAD SCIENCES, INC.
5 paragraphs… Recent developments in the threat landscape include the use of increasingly sophisticated and evolving AI and machine learning tools. Our business and technology partners face similar risks, and any security breach of their systems could adversely affect our security posture.
Item 1A, Risk Factors, 10-K Feb 24, 2026
… In January 2026, the European Medicines Agency and FDA jointly established new artificial intelligence (“AI”) principles in drug development that provide broad guidance on AI use in evidence generation and monitoring across all phases of a medicine’s lifecycle - from …
Item 1A, Risk Factors, 10-K Feb 24, 2026
HUM HUMANA INC
5 paragraphs… These systems require an ongoing commitment of significant resources to maintain, protect, and enhance existing systems and develop and integrate new systems, including systems powered by or incorporating artificial intelligence and machine learning (including generative AI) (AI/ML), to keep …
Item 1A, Risk Factors, 10-K Feb 19, 2026
it harder for us to conduct our business using AI/ML, require us to retrain our AI/ML, delete data produced by our AI/ML, or prevent or limit our use of AI/ML. Our use of AI/ML technologies could also result in additional compliance costs, regulatory investigations, actions, fines or penalties, and consumer or other lawsuits.
Item 1A, Risk Factors, 10-K Feb 19, 2026
INCY INCYTE CORP
5 paragraphsIncreasing use of social media and new technology, including artificial intelligence, could give rise to liability, breaches of data security, or reputational damage.
Item 1A, Risk Factors, 10-K Feb 10, 2026
… Additionally, the use of artificial intelligence is increasing in the biopharmaceutical industry. As with many developing technologies, artificial intelligence presents risks and challenges that could affect its further development, adoption, and use, which could affect our business. If the analyses …
Item 1A, Risk Factors, 10-K Feb 10, 2026
MTD METTLER TOLEDO INTERNATIONAL INC/
5 paragraphs… For instance, it is expected that laws and regulations around the use of AI and machine learning tools will increase over the next few years, but it is unknown at this time what these laws and regulations will address and …
Item 1A, Risk Factors, 10-K Feb 6, 2026
We continue to invest in global market trends around automation and digitalization, as well as technologies related to artificial intelligence (AI). We have several initiatives that further strengthen our capabilities to serve customers, and we continue to advance the digital …
Item 1A, Risk Factors, 10-K Feb 6, 2026
UHS UNIVERSAL HEALTH SERVICES INC
5 paragraphs• $10 million spent in connection with our minority ownership interest in a healthcare generative artificial intelligence company.
Item 7, MD&A, 10-K Feb 25, 2026
• an increase of $93 million from an unrealized gain recorded during 2025 in connection with our minority ownership in a healthcare generative artificial intelligence company;
Item 7, MD&A, 10-K Feb 25, 2026
ABBV AbbVie Inc.
4 paragraphsAdditionally, AbbVie utilizes AI and other emerging technologies in select applications to support its operations. These technologies may present opportunities for AbbVie's business but may also entail risks, including that AI-generated analyses utilized by AbbVie could be deficient …
Item 1A, Risk Factors, 10-K Feb 20, 2026
AbbVie depends on information technology and a failure of, or significant disruption to, those systems, or a failure to adequately adopt emerging technologies such as artificial intelligence, could have a material adverse effect on AbbVie's business.
Item 1A, Risk Factors, 10-K Feb 20, 2026
BIIB BIOGEN INC.
4 paragraphsAs with many developing technologies, AI-based software presents risks and challenges. For example, algorithms may be flawed, data sets may be insufficient, of poor quality or contain biased information; and inappropriate or controversial data practices could impair results. AI …
Item 1A, Risk Factors, 10-K Feb 6, 2026
The increasing use of AI-based software presents new risks and challenges and could adversely affect our business and reputation.
Item 1A, Risk Factors, 10-K Feb 6, 2026
BSX BOSTON SCIENTIFIC CORP
4 paragraphs… Digital technologies, including artificial intelligence (AI) and machine learning capabilities, have and may continue to increase in their applicability and importance to various aspects of our business, operating and competitive environments, research and development (R&D) pipeline and product portfolio …
Item 1A, Risk Factors, 10-K Feb 17, 2026
… This includes emerging technologies which increase our threat landscape, such as generative AI and quantum computing, which are evolving rapidly in their practicality and use for cyber-attacks including through enhanced social engineering, and for cyber-attacks on industry standard …
Item 1A, Risk Factors, 10-K Feb 17, 2026
CAH CARDINAL HEALTH INC
4 paragraphsacross our businesses, to effectively interpret and utilize such data, or protect the integrity of such data, including systems powered by or incorporating artificial intelligence and machine learning, our operations could be impacted, and we may be at a competitive disadvantage.
Item 1A, Risk Factors, 10-K Aug 11, 2026
… If any of these initiatives, including those related to the ongoing implementation of new Enterprise Resource Planning technologies and supply chain optimization initiatives, and initiatives related to artificial intelligence and machine learning, are not successfully or efficiently implemented or maintained …
Item 1A, Risk Factors, 10-K Aug 11, 2026
MRK Merck & Co., Inc.
4 paragraphsThe Company’s growing use of artificial intelligence (AI) systems to automate processes, analyze data, and support decision-making poses inherent risks. Flaws, biases, or malfunctions in these systems could lead to operational disruptions, data loss, or erroneous decision-making …
Item 1A, Risk Factors, 10-K Feb 24, 2026
Furthermore, the deployment of AI systems could expose the Company to increased cybersecurity threats, such as data breaches and unauthorized access leading to financial losses, legal liabilities, and reputational damage. The Company also faces competitive risks if it fails to adopt AI or other machine learning technologies in a timely fashion.
Item 1A, Risk Factors, 10-K Feb 24, 2026
JNJ JOHNSON & JOHNSON
3 paragraphsThe Company leverages the use of data science, machine learning and other forms of AI and emerging technologies across varying parts of its business and operations, and the introduction and incorporation of AI may result in unintended consequences or other …
Item 1A, Risk Factors, 10-K Feb 11, 2026
… The increasing use of AI and other emerging technology could also increase these risks. The Company maintains cybersecurity insurance in the event of an information security or cyber incident; however, the coverage may not be sufficient to cover all financial …
Item 1A, Risk Factors, 10-K Feb 11, 2026
REGN REGENERON PHARMACEUTICALS, INC.
3 paragraphsWe are increasingly utilizing artificial intelligence ("AI")-based solutions in various facets of our operations and continue to explore further use cases for AI. The use of AI solutions by our employees or third parties on which we rely may …
Item 1A, Risk Factors, 10-K Feb 4, 2026
There are inherent risks related to our increasing use of artificial intelligence-based solutions.
Item 1A, Risk Factors, 10-K Feb 4, 2026
STE STERIS plc
3 paragraphs… For instance, generative AI and other artificial intelligence technologies may be used by malicious actors to create more targeted phishing narratives, develop sophisticated malware, spread false information about us or our products, or otherwise enhance the social engineering and attack …
Item 1A, Risk Factors, 10-K May 29, 2026
Likewise, governments and regulatory bodies worldwide are actively developing new laws, regulations and ethical guidelines governing AI use, including the European Union’s Artificial Intelligence Act. Compliance with evolving and potentially inconsistent AI regulations across jurisdictions may be costly and …
Item 1A, Risk Factors, 10-K May 29, 2026
ABT ABBOTT LABORATORIES
1 paragraph… Further, the development of new technologies, including disruptive technologies such as artificial intelligence, healthcare products and medicines, and the development of new treatments for disease could significantly change the competitive landscape of the healthcare industry and negatively impact the demand …
Item 1A, Risk Factors, 10-K Feb 20, 2026
ACAD ACADIA PHARMACEUTICALS INC
0 paragraphsNot mentioned in the latest 10-K.
ACHC Acadia Healthcare Company, Inc.
0 paragraphsNot mentioned in the latest 10-K.
ADMA ADMA BIOLOGICS, INC.
0 paragraphsNot mentioned in the latest 10-K.
ADUS Addus HomeCare Corp
0 paragraphsNot mentioned in the latest 10-K.
AGIO AGIOS PHARMACEUTICALS, INC.
0 paragraphsNot mentioned in the latest 10-K.
ALKS Alkermes plc.
0 paragraphsNot mentioned in the latest 10-K.
ALNY ALNYLAM PHARMACEUTICALS, INC.
0 paragraphsNot mentioned in the latest 10-K.
AMRX Amneal Pharmaceuticals, Inc.
0 paragraphsNot mentioned in the latest 10-K.
AXSM Axsome Therapeutics, Inc.
0 paragraphsNot mentioned in the latest 10-K.
BBIO BridgeBio Pharma, Inc.
0 paragraphsNot mentioned in the latest 10-K.
BCRX BIOCRYST PHARMACEUTICALS INC
0 paragraphsNot mentioned in the latest 10-K.
BEAM Beam Therapeutics Inc.
0 paragraphsNot mentioned in the latest 10-K.
BHC Bausch Health Companies Inc.
0 paragraphsNot mentioned in the latest 10-K.
BKD Brookdale Senior Living Inc.
0 paragraphsNot mentioned in the latest 10-K.
BMRN BIOMARIN PHARMACEUTICAL INC
0 paragraphsNot mentioned in the latest 10-K.
BTSG BrightSpring Health Services, Inc.
0 paragraphsNot mentioned in the latest 10-K.
CAI Caris Life Sciences, Inc.
0 paragraphsNot mentioned in the latest 10-K.
CGON CG Oncology, Inc.
0 paragraphsNot mentioned in the latest 10-K.
CHE CHEMED CORP
0 paragraphsNot mentioned in the latest 10-K.
COO COOPER COMPANIES, INC.
0 paragraphsNot mentioned in the latest 10-K.
SYK STRYKER CORP
0 paragraphsNot mentioned in the latest 10-K.
TECH BIO-TECHNE Corp
0 paragraphsNot mentioned in the latest 10-K.
WST WEST PHARMACEUTICAL SERVICES INC
0 paragraphsNot mentioned in the latest 10-K.